1. Ashok AH, Marques TR, Jauhar, S, Nour MM, Goodwin GM, Young AH et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 2017; 22: 666-679.
2.
Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021; 384: 717-726.
3.
Bunney WE Jr. The current status of research in the catecholamine theories of affective disorders. Psychopharmacol Commun 1975; 1: 599-609.
4.
Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 1972; 51: 11-42.
5.
Carlsson A. Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 1978; 135: 165-173.
6.
Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144.
7.
Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl. 1999; 37: 2-6.
8.
Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004; 11: 267-77.
9.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378: 1306-1315.
10.
Darwish M, Bugarski-Kirola D, Passarell J, Owen J, Jaworowicz D, DeKarske D et al. Pimavanserin exposure-response analyses in patients with schizophrenia: results from the phase 2 ADVANCE study. J Clin Psychopharmacol 2022; 42: 544-551.
11.
Delay J, Deniker P, Harl J-M. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale elective. Ann Méd-Psychol 1952; 110: 112-131.
12.
Divry P, Bobon J, Collard J, Pinchard A, Nois E. Etude et expérimentations cliniques du R 1625 ou halopéridol, nouveau neuroleptique et “neurodysleptique”. Acta Neurol Psychiatr Belg 1959; 59: 337-366.
13.
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204: 282-288.
14.
Fagius J, Osterman PO, Sidén A, Wiholm BE. Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985; 48: 65-69.
15.
Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012; 62: 1473-1483.
16.
Jaracz J, Rybakowski J. Fluwoksamina – najdłużej stosowany lek z grupy selektywnych inhibitorów wychwytu serotoniny. Farmakoter Psychiatr Neurol 2006; 22: 167-175.
17.
Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care. 2002; 38: 157-159.
18.
Ketter TA, Miller S, Dell’Osso B, Wang PW. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord 2016; 191; 256-273.
19.
Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329-336.
20.
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008; 172: 199-212.
21.
Lee T, Seeman P. Dopamine receptors in normal and schizophrenic human brains. Soc Neurosci 1977; Abstr 3: 443.
22.
Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16: 488-501.
23.
Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry Suppl 1992; 17: 22-29.
24.
Möller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1101-1111.
25.
Nasrallah HA, Fedora R, Morton R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr Res 2019; 208: 217-220.
26.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007; 13: 1102-1107.
27.
Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162.
28.
Rybakowski J. Aripiprazol – lek przeciwpsychotyczny trzeciej generacji. Ordynator Lek 2006; 6: 16-20.
29.
Rybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol 2007; 10: 709-711.
30.
Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord 2018; 20: 391-392.
31.
Rybakowski JK. Application of antipsychotic drugs in mood disorders. Brain Sciences 2023: 13: 414.
32.
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-427.
33.
Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
34.
Siwek M, Wojtasik-Bakalarz K. Leki przeciwpsychotyczne. W: Psychofarmakologia kliniczna. Red. Rybakowski J. Państwowy Zakład Wydawnictw Lekarskich, Warszawa 2022, 109-175.
35.
Spiker DG, Perel JM, Hanin I, Dealy RS, Griffin SJ, Soloff PH et al. The pharmacological treatment of delusional depression: Part II. J Clin Psychopharmacol. 1986; 6: 339-342.
36.
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-892.
37.
Tamminga CA. Partial dopamine agonist in the treatment of psychosis. J Neural Trnasm 2002; 109: 411-420.
38.
Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar i disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
39.
Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-494.
40.
Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, Hiyama T. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci. 1988; 42: 1941-1954.
41.
Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71: 150-162.
42.
Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis. J Geriatr Psychiatry Neurol. 2023 Jan 31:8919887231154933. doi: 10.1177/08919887231154933. Online ahead of print.
43.
Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112.
